Arecor Therapeutics (LON:AREC) Sets New 12-Month Low – Should You Sell?

Arecor Therapeutics plc (LON:ARECGet Free Report) reached a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 50 ($0.63) and last traded at GBX 52 ($0.66), with a volume of 3900 shares traded. The stock had previously closed at GBX 52.50 ($0.66).

Arecor Therapeutics Price Performance

The firm has a market cap of £19.63 million, a PE ratio of -1.84 and a beta of -0.18. The company has a debt-to-equity ratio of 5.51, a current ratio of 1.37 and a quick ratio of 6.24. The business’s fifty day moving average is GBX 61.78 and its 200-day moving average is GBX 71.45.

About Arecor Therapeutics

(Get Free Report)

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products.

Featured Articles

Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.